Skip to content

Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient

Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05645185
Acronym
CarMa2
Enrollment
43
Registered
2022-12-09
Start date
2021-10-01
Completion date
2022-10-01
Last updated
2022-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Encephalitis, Paraneoplastic Syndromes

Keywords

Neurological paraneoplastic syndrome, auto immune encephalitis, Ma2 antibody

Brief summary

Paraneoplastic neurological syndromes (PNS) are rare complications of cancer occurring in 0.01% of cases. Their clinical, biological and radiological presentation is heterogeneous and may constitute a diagnostic challenge. Anti-Ma2 PNS are rare diseases with a guarded prognosis. They are most often associated with a seminoma-like testicular tumor but can also be associated with lung cancer. Classically, they present as limbic, diencephalic and/or brainstem encephalitis. Anti-Ma2 antibodies target intracellular receptors and are characteristic of a particular form of encephalitis. Atypical manifestations including narcolepsy-cataplexy, weight gain, sexual dysfunction and motor neuron syndrome have been described and explain the difficulty in diagnosing anti-Ma2 associated PNS. It seems interesting to better characterize the phenotypes of Ma2 patients in order to optimize the diagnosis and follow-up.

Interventions

DIAGNOSTIC_TESTDiagnosis test

Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Neurological disorder * Anti-Ma2 positivity in sera or CSF * Patient \> 18 years old

Exclusion criteria

* Patient without clinical data * Patient without Ma2 antibody in sera or CSF

Design outcomes

Primary

MeasureTime frameDescription
Rankin score12 month after diagnosisFollow up and survival (rankin score)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026